ACCESS Newswire
19 Sep 2023, 17:14 GMT+10
LEXINGTON, MA / ACCESSWIRE / September 19, 2023 / Hyku Biosciences, Inc. (Hyku) today announced its launch with $56 million in seed financing to develop precision covalent medicines in oncology. Hyku is deploying an innovative chemoproteomics platform that selectively disarms disease-causing proteins by covalently targeting ligandable amino acids such as histidines, tyrosines or lysines. Hyku was incubated by RAVen, RA Capital Management's company creation engine, and is based on groundbreaking chemoproteomics research at the University of Virginia by its scientific founder, Dr. Ku-Lung (Ken) Hsu. Dr. Hsu is a recipient of The Mark Foundation's Emerging Leader Award and currently The Stephen F. and Fay Evans Martin Endowed Associate Professor of Chemistry at The University of Texas at Austin.
'Hyku was created with a singular focus to improve patient lives using the power of covalent medicines. Hyku's innovative and unique platform integrates chemoproteomics, proprietary chemistry and bespoke computational and machine-learning algorithms to target critically important amino acids such as histidines, tyrosines and lysines to expand the druggable proteome. We are proud to have a team of accomplished scientists led by our CSO, Mark Mulvihill, PhD, to achieve Hyku's vision.' said Milind Deshpande, Ph.D., Founder, Acting CEO of Hyku and Venture Partner at RA Capital Management.
'Recent progress in covalent medicine has focused largely on targeting cysteines - Hyku builds on that progress, but now targeting proteins and sites only accessible with non-cysteine covalent chemistry,' said Laura Tadvalkar, Ph.D., Managing Director at RA Capital Management and Hyku Board member. 'We are proud to see the progress Hyku has made since its inception.'
'We believe that precision covalent medicines provide a promising approach to address current and emerging challenges in oncology. Hyku's in-house chemoproteomics platform allows the team to make rapid progress across a range of pipeline programs - both internal and potentially with partners in the future. We look forward to working with the Hyku team and support their bold vision,' said Matthias Van Woensel, Ph.D., Partner at Droia Ventures and Hyku Board member.
About Hyku Biosciences
Hyku Biosciences is a biotechnology company, based in the greater Boston area, building the leading covalent medicines discovery platform to inhibit disease targets which are challenging to address with conventional approaches. Hyku's drug discovery engine is based on its proprietary platform technologies, which identifies histidine, tyrosine and lysine based binding pockets and enables rational drug design for therapeutic development. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase druggability across many target classes, and bring significant therapeutic benefits to patients via novel medicines. For more information, visit http://www.hykubiosciences.com
Contact:
SOURCE: Hyku Biosciences, Inc.
Get a daily dose of Business Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Business Sun.
More InformationREDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
LONDON UK - U.S. stock markets were closed on Friday for Independence Day. Global Forex Markets Wrap Up Friday with Greeback Comeback...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SACRAMENTO, California: California's multibillion-dollar farms are facing a growing crisis—not from drought or pests, but from a sudden...
WASHINGTON, D.C.: President Donald Trump says the United States could soon reach a trade deal with India. He believes this deal would...
SAN FRANCISCO, California: Grammarly is doubling down on AI-powered productivity tools with the acquisition of Superhuman, a sleek...
REDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SAN FRANCISCO, California: Grammarly is doubling down on AI-powered productivity tools with the acquisition of Superhuman, a sleek...
SANTA CLARA, California: Executives at Nvidia have quietly been cashing in on the AI frenzy. According to a report by the Financial...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
Bengaluru (Karnataka) [India], July 5 (ANI): Union Minister of Commerce and Industry Piyush Goyal, during an interactive session with...